XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases

CRISPR & Gene Editing

January 10, 2022 by Kevin Kelly

The breaking news this week in gene editing was Pfizer Inc. will pay as much as $1.35 billion to partner with Beam Therapeutics Inc. on developing drugs for rare genetic diseases using base editing, a technology for manipulating DNA.

From Barron’s:

Gene editing is the next phase of genetic medicine, and another big step was just announced. Monday morning, Pfizer unveiled a $1.3 billion partnership with Beam Therapeutics to develop three treatments for genetic disease in the next four years. They’ll use Beam’s leading-edge technology that makes precise corrections to typographical errors in our genes—a technology called “base editing”.

Beam is a top constituent in the XDNA Index

 

Recent Blog

How to Invest in Free Cash Flow Yield

How to Invest in Free Cash Flow Yield

November 2, 2023
The Market’s Two August Super Moons: Tech Earnings and the Fed

The Market’s Two August Super Moons: Tech Earnings and the Fed

July 12, 2023
Barron’s: 6 Apartment Stocks That Get a Rise Out of High Home Prices

Barron’s: 6 Apartment Stocks That Get a Rise Out of High Home Prices

July 19, 2022
NBC News: Extended stay hotels play the long game – HOTL

NBC News: Extended stay hotels play the long game – HOTL

February 23, 2022
HOTL Earnings: Global Travel Set to Rebound in 2022

HOTL Earnings: Global Travel Set to Rebound in 2022

February 16, 2022

Related Blog

How to Invest in Free Cash Flow Yield

How to Invest in Free Cash Flow Yield

DOWNLOAD THIS REPORT HERE (PDF) Free Cash Flow (“FCF”) Yield is one of the most important fundamental metrics indicating a...
Read More
The Market’s Two August Super Moons: Tech Earnings and the Fed

The Market’s Two August Super Moons: Tech Earnings and the Fed

The equities market has some weird energy this year with two strong energy fields driving returns and sentiment. The Fed...
Read More
Barron’s: 6 Apartment Stocks That Get a Rise Out of High Home Prices

Barron’s: 6 Apartment Stocks That Get a Rise Out of High Home Prices

Apartments are a critical component of the RESI Index , and the overall housing market, as housing is undergoing a...
Read More
NBC News: Extended stay hotels play the long game – HOTL

NBC News: Extended stay hotels play the long game – HOTL

We believe the hotel and lodging sector acts as an effective economic barometer as it uniquely captures both leisure and...
Read More
HOTL Earnings: Global Travel Set to Rebound in 2022

HOTL Earnings: Global Travel Set to Rebound in 2022

The Hotel and Lodging Sector acts as an effective economic barometer as it uniquely captures both leisure and business spending...
Read More
Barron’s: This RESI Home Rental Stock Is One Way to Play the Hot Housing Market

Barron’s: This RESI Home Rental Stock Is One Way to Play the Hot Housing Market

Kelly Intelligence believes that the residential and apartment ("multifamily") industry, via the RESI Index, is undergoing a seismic change due...
Read More
XDNA: 2022 is Set To Bring Exciting Developments for Gene Editing

XDNA: 2022 is Set To Bring Exciting Developments for Gene Editing

Last year ended difficulty for publicly traded gene editing companies but at J.P. Morgan’s virtual healthcare conference this week, gene-editing...
Read More
XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases

XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases

The breaking news this week in gene editing was Pfizer Inc. will pay as much as $1.35 billion to partner...
Read More
XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma – Mammoth & Bayer

XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma – Mammoth & Bayer

CRISPR & Gene Editing companies are making waves in 2022, including start-ups, which is validating the technology's promise on disrupting...
Read More
WSJ: RESI – Millennials Are Supercharging the Housing Market

WSJ: RESI – Millennials Are Supercharging the Housing Market

The Wall Street Journal came out with an feature, Millennials Are Supercharging the Housing Market, which focuses on "The generation...
Read More
WSJ: Soaring Rents Make It a Very Good Time to Own an Apartment Building

WSJ: Soaring Rents Make It a Very Good Time to Own an Apartment Building

The Wall Street Journal's Property Report published, Soaring Rents Make It a Very Good Time to Own an Apartment Building,...
Read More
RESI: Sam Zell’s Equity Residential Partners With Toll on $1.9 Billion Apartment Deal

RESI: Sam Zell’s Equity Residential Partners With Toll on $1.9 Billion Apartment Deal

The evolving and residential housing boom continues and Bloomberg put it best: Sam Zell’s Equity Residential and the luxury homebuilder...
Read More
{"slide_show":"4","slide_scroll":1,"dots":"false","arrows":"true","autoplay":"true","autoplay_interval":"5000","speed":600,"loop":"true","design":"design-1"}

It is not possible to invest directly in an index. Exposure to an asset class represented by an index is available through investable instruments based on that index. Strategic Investments does not sponsor, endorse, sell, promote or manage any investment fund or other investment vehicle that is offered by third parties and that seeks to provide an investment return based on the performance of any index. Strategic Investments licenses its indices to third parties for the creation of investment funds or other vehicles, such as exchange-traded funds (ETFs), exchange-traded notes (ETNs), institutional asset mandates, and structured notes.

The information contained does not reflect the performance of any fund or account managed or serviced by Strategic Investments, and there is no guarantee that investors will experience the type of performance reflected above. There is no guarantee that any historical trend illustrated herein will be repeated in the future, and there is no way to predict precisely when such a trend will begin. There is no guarantee that any market forecast made in this commentary will be realized. The mention of specific securities is not a recommendation or solicitation for any person to buy, sell or hold any particular security and should not be relied upon as investment advice. The views and opinions in the preceding commentary are as of the date of publication and are subject to change without notice. This material represents an assessment of the market environment at a specific point in time, should not be relied upon as investment advice, is not intended to predict or depict performance of any investment and does not constitute a recommendation or an offer for a particular security. We consider the information in this presentation to be accurate, but we do not represent that it is complete or should be relied upon as the sole source of suitability for investment.